E
ALLO icon

Ergoteles’s Allogene Therapeutics ALLO Stock Holding History

Ergoteles’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-76,675
Closed -$874K – 1516
2022
Q2 		$874K Buy
76,675
+11,116
+17% +$98.7K 0.03% 600
2022
Q1 		$597K Sell
65,559
-5,127
-7% -$53.4K 0.02% 609
2021
Q4 		$1.05M Buy
70,686
+20,203
+40% +$356K 0.04% 405
2021
Q3 		$1.3M Buy
+50,483
New +$1.2M 0.05% 331
2021
Q2 		– Sell
-74,276
Closed -$2.62M – 1467
2021
Q1 		$2.62M Buy
+74,276
New +$2.51M 0.08% 244

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ergoteles's ALLO Position: Q3 2022 in Review

Ergoteles sold out of Allogene Therapeutics (ALLO) in Q3 2022, closing a stake of 76,675 shares — an estimated $874K sold.

Ergoteles first reported a position in ALLO in Q1 2021 and held it in 5 quarters. The position peaked at $2.62M in Q1 2021. 192 funds tracked by Wall St. Rank hold ALLO as of Q3 2022.

  • Ergoteles reported no remaining Allogene Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 76,675 Allogene Therapeutics shares in Q3 2022, an estimated $874K.
  • Ergoteles first reported a position in Allogene Therapeutics in Q1 2021 and held it in 5 quarters.
  • Ergoteles's Allogene Therapeutics position peaked at $2.62M in Q1 2021.
  • 192 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.